Should we treatBlastocystissp.? A double-blind placebo-controlled randomized pilot trial
Open Access
- 28 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 30 (1)
Abstract
Blastocystis sp. is a worldwide-distributed protist colonizing the guts of humans and a great variety of animals. It is unclear whether it is just a commensal or an infectious parasite that prompts eradication. The main objective of this study was to evaluate the usefulness of metronidazole in patients with gastrointestinal symptoms harbouring only Blastocystis sp. In addition, we explored whether Blastocystis subtype or concomitant parasitic infection detected by polymerase chain reaction (PCR) may influence treatment outcome. We included adults with persistent gastrointestinal symptoms (>14 days) visiting a primary care physician and in whom stool microscopy revealed only Blastocystis sp. Eligible patients were randomized to receive ten days of metronidazole or placebo, followed by a crossover if still symptomatic. The primary outcome was normal stool consistency. Secondary outcomes were the changes in other abdominal symptoms (bloating, flatulence, abdominal pain, number of daily bowel movements) and general wellbeing. After the clinical phase of the study, Blastocystis subtypes were determined by PCR sequencing and stool samples were tested for 11 other protozoa with an in-house PCR. We screened 581 outpatients for inclusion, of which 50 met the eligibility criteria. There was no difference in the primary outcome, nor any of the secondary outcomes between the subjects treated with metronidazole and placebo. The most frequent Blastocystis subtypes were ST4 (11/36) and ST2 (10/36). The in-house PCR was positive for other protozoa in 25% (10/40) of the patients. We identified Dientamoeba fragilis in 5, Entamoeba dispar in 3 and Cyclospora cayetanensis in 2 patients. Stratified analysis according to Blastocystis subtype or the presence of other protozoa showed no significant difference in treatment outcome with metronidazole or placebo. Among patients infected with Blastocystis sp., metronidazole, compared with placebo, was not better in improving gastrointestinal symptoms, irrespective of subtype or microscopically undetected coinfection with other protozoa.Keywords
All Related Versions
Funding Information
- Loterie Romande
This publication has 19 references indexed in Scilit:
- Molecular Epidemiology of Blastocystis in Lebanon and Correlation between Subtype 1 and Gastrointestinal SymptomsThe American Journal of Tropical Medicine and Hygiene, 2013
- Variable geographic distribution of Blastocystis subtypes and its potential implicationsActa Tropica, 2013
- Development and Evaluation of a Genus-Specific, Probe-Based, Internal-Process-Controlled Real-Time PCR Assay for Sensitive and Specific Detection of Blastocystis sppJournal of Clinical Microbiology, 2012
- Blastocystis sp. Subtype 4 is Common in Danish Blastocystis-Positive Patients Presenting with Acute DiarrheaThe American Journal of Tropical Medicine and Hygiene, 2011
- Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infectionParasitology Research, 2010
- High prevalence of subtype 4 among isolates of Blastocystis hominis from symptomatic patients of a health district of Valencia (Spain)Parasitology Research, 2009
- New Insights on Classification, Identification, and Clinical Relevance ofBlastocystissppClinical Microbiology Reviews, 2008
- Predominance of subtype 3 among Blastocystis isolates from a major hospital in SingaporeParasitology Research, 2007
- DNA Barcoding of BlastocystisProtist, 2006
- Effect of Nitazoxanide in Persistent Diarrhea and Enteritis Associated With Blastocystis hominisClinical Gastroenterology and Hepatology, 2005